Last reviewed · How we verify
NCT06211972
The Feasibility of the OpiVenture Program for Clients Undergoing Opioid Agonist Therapy
NA trial testing OpiVenture in Opioid Use Disorder in 96 participants. Not yet recruiting.
1 February 2025
Quick facts
| Lead sponsor | Dalhousie University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 96 |
| Start date | 15 October 2024 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 February 2026 |
Drugs / interventions tested
- OpiVenture
Conditions studied
- Opioid Use Disorder — all drugs for Opioid Use Disorder →
- Polysubstance Addiction — all drugs for Polysubstance Addiction →
- Substance Use — all drugs for Substance Use →
Sponsor
Dalhousie University
Who can join
18 and older, any sex, with Opioid Use Disorder or Polysubstance Addiction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The opioid crisis continues its devastating impact on Canada, with over 13,900 deaths recorded between 2016 and 2019. Dangerous prescription opioid usage persists, affecting 12.3% of Canadians in 2018. The crisis has escalated, particularly during the COVID-19 pandemic, resulting in increased mortality rates. While opioid agonist therapy (OAT) is a common treatment, it falls short in addressing concurrent polysubstance use, a prevalent issue in OAT clients. Recognizing the limitations of OAT alone, there is a growing recommendation to supplement it with psychosocial interventions. The PreVenture program, known for its efficacy in reducing substance use, has been adapted for OAT clients, termed "OpiVenture." This study aims to comprehensively assess OpiVenture's feasibility and limited efficacy within an OAT setting. Utilizing a mixed-methods approach, the study design integrates qualitative and quantitative data collection methods to thoroughly evaluate the program's feasibility and preliminary effectiveness. The focus extends beyond immediate outcomes, encompassing the preparation for future randomized controlled trials, including considerations for sample size calculation and recruitment effectiveness. This research addresses the urgent need for more comprehensive interventions to mitigate opioid use disorder (OUD) and associated morbidity, offering a potential solution to improve OAT retention and reduce mortality rates.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06211972
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid Use Disorder
Currently open trials in the same condition.
- NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
- NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
- NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
Other Dalhousie University trials
Trials by the same sponsor.
- NCT07305207 — Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness · Phase 1 · not yet recruiting
- NCT06827470 — Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella Pertussis · Phase 1 · recruiting
- NCT06777277 — Cognitive-Behavioural Couple Therapy for Sexual Interest/Arousal Disorder · NA · recruiting
- NCT06588049 — Nitrate Mouth Rinse and the Oral Microbiome · NA · completed
- NCT06748833 — An App Responding to Behaviour of People to Promote Mental Wellbeing in Anxious Youth · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06211972 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dalhousie University
- Last refreshed: 30 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06211972.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing